William A. Clark, Ph.D. – Vice President of Science and Strategic Alliances
Drawing upon his expertise in pharmacology, protein expression and purification, genetic engineering and assay development, Dr. Clark directs PBL’s business development and intellectual property efforts. He also negotiates research, alliance, service, consulting and licensing arrangements with pharmaceutical and biotechnology companies, universities and government laboratories. Dr. Clark earned degrees from Boston College and Yale University, and completed his postdoctoral fellowship at the NIH.
Gregory Davies, MBA – Corporate Controller
Mr. Davies is responsible for managing PBL’s financial functions. He has more than 18 years of financial experience in a variety of industries including supporting an initial public offering and coordinating various debt and equity financing transactions. Mr. Davies received a Bachelor of Science in management from Montclair State University and an M.B.A. in finance from Monmouth University.
Thomas B. Lavoie, Ph.D. – Chief Scientific Officer
Dr. Lavoie’s team produces the proteins for PBL’s products, researches and develops new products and provides custom assay services for clients. He is also an essential part of the Business Development team. Prior to PBL, Dr. Lavoie developed assays and proteins for structure based drug discovery at BMS, conducted research at the NIH and received degrees from Frostburg State and UMCP.
